Fig. 3
a CLSM images of SKOV-3 cells after 2 h incubation with Cy5.5@mPDA/MnO2/PDA NPs and Cy5.5@mPDA/MnO2/PDA-ZHer2 NPs and after a 1 h pre-treatment with or without ZHer2. b Flow cytometry data for untreated SKOV-3 cells, SKOV-3 cells incubated for 4 h with Cy5.5@mPDA/MnO2/PDA NPs or Cy5.5@mPDA/MnO2/PDA-ZHer2 NPs, and cells pre-incubated with ZHer2 for 1 h before being exposed to Cy5.5@mPDA/MnO2/PDA-ZHer2 NPs for 4 h, and fluorescence intensity quantified. c MTT viability results for SKOV-3 cells after incubation with free cisplatin (Pt), Pt@mPDA/MnO2/PDA NPs, and Pt@mPDA/MnO2/PDA-ZHer2 NPs for 24 h. d Fluorescence images of calcein-AM/PI co-stained SKOV-3 cells after different treatments (dose of cisplatin: 48 μg/mL). e Intracellular ROS levels in SKOV-3 cells after treatment with different formulations